128 related articles for article (PubMed ID: 35710751)
1. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
Kotsopoulos J; Zamani N; Rosen B; McLaughlin JR; Risch HA; Kim SJ; Sun P; Akbari MR; Narod SA
Br J Cancer; 2022 Sep; 127(5):879-885. PubMed ID: 35710751
[TBL] [Abstract][Full Text] [Related]
2. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH
Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979
[TBL] [Abstract][Full Text] [Related]
5. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
9. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
10. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Candido-dos-Reis FJ; Song H; Goode EL; Cunningham JM; Fridley BL; Larson MC; Alsop K; Dicks E; Harrington P; Ramus SJ; de Fazio A; Mitchell G; Fereday S; Bolton KL; Gourley C; Michie C; Karlan B; Lester J; Walsh C; Cass I; Olsson H; Gore M; Benitez JJ; Garcia MJ; Andrulis I; Mulligan AM; Glendon G; Blanco I; Lazaro C; Whittemore AS; McGuire V; Sieh W; Montagna M; Alducci E; Sadetzki S; Chetrit A; Kwong A; Kjaer SK; Jensen A; Høgdall E; Neuhausen S; Nussbaum R; Daly M; Greene MH; Mai PL; Loud JT; Moysich K; Toland AE; Lambrechts D; Ellis S; Frost D; Brenton JD; Tischkowitz M; Easton DF; Antoniou A; Chenevix-Trench G; Gayther SA; Bowtell D; Pharoah PD; ; ;
Clin Cancer Res; 2015 Feb; 21(3):652-7. PubMed ID: 25398451
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
12. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer onset across different
Marchetti C; Ataseven B; Cassani C; Sassu CM; Congedo L; D'Indinosante M; Cappuccio S; Rhiem K; Hahnen E; Lucci Cordisco E; Arbustini E; Harter P; Minucci A; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):257-262. PubMed ID: 36581488
[TBL] [Abstract][Full Text] [Related]
16. Germline BRCA variants, lifestyle and ovarian cancer survival.
Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; ; ; Webb PM
Gynecol Oncol; 2022 Jun; 165(3):437-445. PubMed ID: 35400525
[TBL] [Abstract][Full Text] [Related]
17. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Cowan R; Nobre SP; Pradhan N; Yasukawa M; Zhou QC; Iasonos A; Soslow RA; Arnold AG; Trottier M; Catchings A; Roche KL; Gardner G; Robson M; Abu Rustum NR; Aghajanian C; Cadoo K
Gynecol Oncol; 2021 May; 161(2):521-526. PubMed ID: 33712278
[TBL] [Abstract][Full Text] [Related]
19. Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.
Kotsopoulos J; Hathaway CA; Narod SA; Teras LR; Patel AV; Hu C; Yadav S; Couch FJ; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1402-1410. PubMed ID: 37493628
[TBL] [Abstract][Full Text] [Related]
20. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
